PDCD1LG2 and cancer: Programmed death receptor-1/programmed death receptor ligands-1 (PD-1/PD-L1/PD-L2) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or HER are among the most common and promising targets for cancer immunotherapy [37].